Colon Cancer |
Cholangiocarcinoma |
Clinical Trial: Capecitabine in Treating Older Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed
This study is no longer recruiting patients.
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating older patients who have metastatic or recurrent colorectal cancer that cannot be surgically removed.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| recurrent colon cancer stage IV colon cancer recurrent rectal cancer Stage IV rectal cancer | Drug: capecitabine Procedure: chemotherapy | Phase II |
MedlinePlus related topics: Colorectal Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of Capecitabine in Elderly Patients With Unresectable Metastatic or Recurrent Colorectal Cancer
OBJECTIVES:
- Determine the feasibility of enrolling patients aged 70 and over with unresectable metastatic or recurrent colorectal cancer to a structured phase II study.
- Determine the anticancer efficacy of capecitabine, in terms of objective response rate (confirmed and unconfirmed, complete and partial responses) and 2-year survival, in these patients.
- Determine the toxicity and tolerability of this drug in these patients.
- Determine the feasibility of using standardized self-report measures of comorbidity, depression, and functional status of patients treated with this drug.
- Determine the clinical pharmacology of this drug in these patients.
- Determine whether patients under 60 years of age treated with this drug have clinical pharmacologic parameters similar to those reported in the literature.
OUTLINE: This is a multicenter study. Patients are stratified according to age (70 and over vs 18 to 59).
Patients receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 80 patients (60 patients aged 70 and over, 20 patients aged 18 to 59) will be accrued for this study.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed metastatic or recurrent colorectal cancer not amenable to surgical resection
- Measurable disease
- No known brain metastases by MRI or CT scan
PATIENT CHARACTERISTICS: Age
- 70 and over OR
- 18 to 59
Performance status
- Zubrod 0-2
Life expectancy
- Not specified
Hematopoietic
- Absolute granulocyte count at least 1,000/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Bilirubin no greater than 2 times upper limit of normal (ULN)
- SGOT or SGPT no greater than 2 times ULN
Renal
- Creatinine no greater than 2 times ULN
- Creatinine clearance greater than 50 mL/min
Other
- Not pregnant or nursing
- Fertile patients must use effective contraception
- HIV negative
- No known seizure disorder
- No other malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, adequately treated stage I or II cancer currently in complete remission, or any other cancer for which the patient has been disease free for 5 years
PRIOR CONCURRENT THERAPY: Biologic therapy
- Not specified
Chemotherapy
- No prior chemotherapy for advanced cancer
- Prior adjuvant chemotherapy allowed provided recurrence occurred more than 1 year after the last treatment
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Other
- At least 4 weeks since prior sorivudine or brivudine
- No concurrent sorivudine or brivudine
Location Information
Alabama
MBCCOP - Gulf Coast, Mobile, Alabama, 36607, United States
Arizona
Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, 85724, United States
CCOP - Western Regional, Arizona, Phoenix, Arizona, 85006-2726, United States
Veterans Affairs Medical Center - Phoenix (Carl T. Hayden), Phoenix, Arizona, 85012, United States
Veterans Affairs Medical Center - Tucson, Tucson, Arizona, 85723, United States
Arkansas
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States
Veterans Affairs Medical Center - Little Rock, Little Rock, Arkansas, 72205, United States
California
CCOP - Bay Area Tumor Institute, Oakland, California, 94609-3305, United States
CCOP - Santa Rosa Memorial Hospital, Santa Rosa, California, 95403, United States
Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center, Orange, California, 92868, United States
City of Hope Comprehensive Cancer Center, Duarte, California, 91010-3000, United States
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, 90095-1781, United States
University of California Davis Cancer Center, Sacramento, California, 95817, United States
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, 90033, United States
Veterans Affairs Medical Center - Loma Linda (Pettis), Loma Linda, California, 92357, United States
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, 94553, United States
Colorado
University of Colorado Cancer Center at University of Colorado Health Sciences Center, Aurora, Colorado, 80010, United States
Veterans Affairs Medical Center - Denver, Denver, Colorado, 80220, United States
District of Columbia
MBCCOP - Howard University Cancer Center, Washington, District of Columbia, 20060, United States
Florida
Veterans Affairs Medical Center - Tampa (Haley), Tampa, Florida, 33612, United States
Georgia
CCOP - Atlanta Regional, Atlanta, Georgia, 30342-1701, United States
Hawaii
MBCCOP - Hawaii, Honolulu, Hawaii, 96813, United States
Illinois
Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, 60153-5500, United States
CCOP - Central Illinois, Decatur, Illinois, 62526, United States
MBCCOP - University of Illinois at Chicago, Chicago, Illinois, 60612, United States
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, 60612, United States
Veterans Affairs Medical Center - Hines, Hines, Illinois, 60141, United States
Kansas
CCOP - Wichita, Wichita, Kansas, 67214-3882, United States
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, 66160-7353, United States
Veterans Affairs Medical Center - Wichita, Wichita, Kansas, 67218, United States
Kentucky
Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington, Kentucky, 40536-0084, United States
Veterans Affairs Medical Center - Lexington, Lexington, Kentucky, 40502-2236, United States
Louisiana
Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, 71130-3932, United States
MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana, 70112, United States
Tulane Cancer Center at Tulane University Hospital and Clinic, New Orleans, Louisiana, 70112, United States
Veterans Affairs Medical Center - New Orleans, New Orleans, Louisiana, 70112, United States
Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, 71101-4295, United States
Massachusetts
Cancer Research Center at Boston Medical Center, Boston, Massachusetts, 02118, United States
Michigan
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, 48201-1379, United States
CCOP - Beaumont, Royal Oak, Michigan, 48073-6769, United States
CCOP - Grand Rapids, Grand Rapids, Michigan, 49503, United States
CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, 48106, United States
Josephine Ford Cancer Center at Henry Ford Health System, Detroit, Michigan, 48202, United States
Providence Cancer Institute at Providence Hospital - Southfield, Southfield, Michigan, 48075, United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109-0948, United States
Veterans Affairs Medical Center - Detroit, Detroit, Michigan, 48201-1932, United States
Mississippi
University of Mississippi Medical Center, Jackson, Mississippi, 39216-4505, United States
Veterans Affairs Medical Center - Jackson, Jackson, Mississippi, 39216, United States
Missouri
CCOP - Cancer Research for the Ozarks, Springfield, Missouri, 65807, United States
CCOP - Kansas City, Kansas City, Missouri, 64131, United States
CCOP - St. Louis-Cape Girardeau, Saint Louis, Missouri, 63141, United States
St. Louis University Hospital Cancer Center, Saint Louis, Missouri, 63110, United States
Montana
CCOP - Montana Cancer Consortium, Billings, Montana, 59101, United States
New Mexico
MBCCOP - University of New Mexico HSC, Albuquerque, New Mexico, 87131, United States
Veterans Affairs Medical Center - Albuquerque, Albuquerque, New Mexico, 87108-5138, United States
New York
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, 10032, United States
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, 14642, United States
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, 10016, United States
North Carolina
CCOP - Southeast Cancer Control Consortium, Goldsboro, North Carolina, 27534-9479, United States
Ohio
CCOP - Columbus, Columbus, Ohio, 43206, United States
CCOP - Dayton, Dayton, Ohio, 45429, United States
Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio, 45267-0501, United States
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, 44195-9001, United States
Veterans Affairs Medical Center - Cincinnati, Cincinnati, Ohio, 45220-2288, United States
Veterans Affairs Medical Center - Dayton, Dayton, Ohio, 45428-1002, United States
Oklahoma
Oklahoma University Medical Center, Oklahoma City, Oklahoma, 73104, United States
Oregon
Cancer Institute at Oregon Health and Science University, Portland, Oregon, 97201-3098, United States
CCOP - Columbia River Oncology Program, Portland, Oregon, 97225, United States
Veterans Affairs Medical Center - Portland, Portland, Oregon, 97207, United States
South Carolina
CCOP - Greenville, Greenville, South Carolina, 29615, United States
CCOP - Upstate Carolina, Spartanburg, South Carolina, 29303, United States
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, 29425, United States
Veterans Affairs Medical Center - Charleston, Charleston, South Carolina, 29401-5799, United States
Tennessee
University of Tennessee Cancer Institute at Methodist Central Hospital, Memphis, Tennessee, 38104, United States
Veterans Affairs Medical Center - Memphis, Memphis, Tennessee, 38104, United States
Texas
Brooke Army Medical Center, Fort Sam Houston, Texas, 78234-6200, United States
CCOP - Scott and White Hospital, Temple, Texas, 76508, United States
Harrington Cancer Center, Amarillo, Texas, 79106, United States
University of Texas - MD Anderson Cancer Center, Houston, Texas, 77030-4095, United States
University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229-3900, United States
University of Texas Medical Branch, Galveston, Texas, 77555-0565, United States
Veterans Affairs Medical Center - Amarillo, Amarillo, Texas, 79106, United States
Veterans Affairs Medical Center - San Antonio (Murphy), San Antonio, Texas, 78229, United States
Veterans Affairs Medical Center - Temple, Temple, Texas, 76504, United States
Utah
Huntsman Cancer Institute, Salt Lake City, Utah, 84112-5550, United States
Veterans Affairs Medical Center - Salt Lake City, Salt Lake City, Utah, 84148, United States
Washington
CCOP - Northwest, Tacoma, Washington, 98405-0986, United States
CCOP - Virginia Mason Research Center, Seattle, Washington, 98101, United States
Puget Sound Oncology Consortium, Seattle, Washington, 98109, United States
Veterans Affairs Medical Center - Seattle, Seattle, Washington, 98108, United States
Heinz-Josef Lenz, MD, Study Chair, University of Southern California
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Record last reviewed: January 2005
Last Updated: January 6, 2005
Record first received: November 12, 2002
ClinicalTrials.gov Identifier: NCT00049335
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005
Resources
- Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC (Google Health)
- Asian Pacific Islander National Cancer Survivors Network (Asian and Pacific Islander American Health Forum)

Not Signed In -

